<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39449074</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2042-6410</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Biology of sex differences</Title><ISOAbbreviation>Biol Sex Differ</ISOAbbreviation></Journal><ArticleTitle>Aromatase, testosterone, TMPRSS2: determinants of COVID-19 severity.</ArticleTitle><Pagination><StartPage>84</StartPage><MedlinePgn>84</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">84</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13293-024-00658-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Male sex has been identified as a risk factor for worse COVID-19 outcomes. This sex difference has been mostly attributed to the complex role of sex hormones. Cell surface entry of SARS-CoV-2 is mediated by the transmembrane protease serine 2 (TMPRSS2) which is under transcriptional regulation by androgens. P450 aromatase enzyme converts androgens to estrogens. This study measured concentrations of aromatase enzyme, testosterone, estradiol, and TMPRSS-2 in plasma of hospitalized COVID-19 patients to elucidate the dynamics of sex-linked disparity in COVID-19 and correlate them with disease severity and mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective cohort study, a total of 265 patients (41% women), age 18 years and older, who had a positive COVID-19 PCR test and were hospitalized for COVID-19 at Memorial Hermann Hospital in Houston, (between May 2020 and May 2021) were enrolled in the study if met inclusion criteria. Plasma concentrations of Testosterone, aromatase, TMPRSS-2, and estradiol were measured by ELISA. COVID-19 patients were dichotomized based on disease severity into moderate-severe (n = 146) or critical (n = 119). Mann Whitney U and logistic regression were used to correlate the analytes with disease severity and mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">TMPRSS2 (2.5 ± 0.31 vs. 1.73 ± 0.21 ng/mL, p &lt; 0.01) and testosterone (1.2 ± 0.1 vs. 0.44 ± 0.12 ng/mL, p &lt; 0.01) were significantly higher in men as compared to women with COVID-19 after adjusting for age in a multivariate model. There was no sex difference seen in the level of estradiol and aromatase in COVID-19 patients. TMPRSS2 and aromatase were higher, while testosterone was lower in patients with increased COVID-19 severity. They were independently associated with COVID-19 severity, after adjusting for several baseline risk factors in a multivariate logistic regression model. In terms of mortality, TMPRRS2 and aromatase levels were significantly higher in non-survivors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study demonstrates that testosterone, aromatase, and TMPRSS2 are markers of COVID-19 severity. Estradiol levels do not change with disease severity in COVID-19. In terms of mortality prediction, higher aromatase and TMPRSS-2 levels can be used to predict mortality from COVID-19 in hospitalized patients. COVID-19 has caused over a million deaths in the U.S., with men often getting sicker than women. Testosterone, a male hormone, helps control a protein called TMPRSS-2, which allows the COVID-19 virus to spread more easily in the body. A protein called aromatase converts the male hormone testosterone into the female hormone estrogen. It is thought that female hormone estrogen helps protect women from getting seriously ill from COVID-19. To understand the role of these hormones in COVID-19 and sex differences, we measured levels of testosterone, estrogen, aromatase (which turns testosterone into estrogen), and TMPRSS-2 in hospitalized COVID-19 patients. We also checked how this level might reflect the severity of the disease. We found that critically ill COVID-19 patients (the ones in ICU) had higher levels of TMPRSS-2 and aromatase, and lower testosterone levels. When we used these hormone levels to predict death in hospitalized COVID-19 patients, higher levels of TMPRSS-2 and aromatase were linked to a lower chance of survival.</AbstractText><CopyrightInformation>© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savarraj</LastName><ForeName>Jude P J</ForeName><Initials>JPJ</Initials><AffiliationInfo><Affiliation>Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colpo</LastName><ForeName>Gabriela D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Carson E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAlister</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahnstedt</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>HuiMahn</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Louise D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manwani</LastName><ForeName>Bharti</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA. Bharti.manwani@uth.tmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01MH127856</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>20CDA35310306</GrantID><Agency>American Heart Association</Agency><Country /></Grant><Grant><GrantID>R21AG070860</GrantID><Agency>NATIONAL INSTITUTE OF AGING</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biol Sex Differ</MedlineTA><NlmUniqueID>101548963</NlmUniqueID><ISSNLinking>2042-6410</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C421305">TMPRSS2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D001141">Aromatase</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="Y">Testosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="Y">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001141" MajorTopicYN="Y">Aromatase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aromatase</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">CRP</Keyword><Keyword MajorTopicYN="N">Sex differences</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39449074</ArticleId><ArticleId IdType="doi">10.1186/s13293-024-00658-4</ArticleId><ArticleId IdType="pii">10.1186/s13293-024-00658-4</ArticleId><ArticleId IdType="pmc">PMC11515603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Le T-T, Liao X. Two-part predictive modeling for COVID-19 cases and deaths in the U.S. PLoS ONE. 2024;19:e0302324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156282</ArticleId><ArticleId IdType="pubmed">38843223</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Management. of COVID-19: Living GuidelineWorld Health Organization, Geneva,. (2022).</Citation></Reference><Reference><Citation>Peckham H, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11:6317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7726563</ArticleId><ArticleId IdType="pubmed">33298944</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabião J, et al. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Braz J Med Biol Res. 2022;55:e11711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8856598</ArticleId><ArticleId IdType="pubmed">35195196</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23:3–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q, Rasool RU, Russell RM, Natesan R, Asangani IA. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience 24, 102254 (2021).</Citation></Reference><Reference><Citation>Mikkonen L, Pihlajamaa P, Sahu B, Zhang F-P, Jänne OA. Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol. 2010;317:14–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">20035825</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman AW, Litwack G. Steroid hormones: Chemistry, Biosynthesis, and metabolism. In hormones (Academic).</Citation></Reference><Reference><Citation>McCARTHY MM. Estradiol and the developing brain. Physiol Rev. 2008;88:91–134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754262</ArticleId><ArticleId IdType="pubmed">18195084</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabbir S, Hafeez A, Rafiq MA, Khan MJ. Estrogen shields women from COVID-19 complications by reducing ER stress. Med Hypotheses. 2020;143:110148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390780</ArticleId><ArticleId IdType="pubmed">32759016</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington NL, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell. 2021;184:2587–e25947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009040</ArticleId><ArticleId IdType="pubmed">33861950</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 Virus. Cell. 2020;182:812–e82719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633005</ArticleId><ArticleId IdType="pubmed">19087314</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>US Preventive Services Task Force. Hormone therapy for the primary Prevention of Chronic conditions in Postmenopausal persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328:1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">36318127</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. 117, 7001–7003 (2020).</Citation></Reference><Reference><Citation>Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–e2808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Glowacka I, et al. Evidence that TMPRSS2 activates the severe Acute Respiratory Syndrome Coronavirus spike protein for membrane Fusion and reduces viral control by the Humoral Immune Response. J Virol. 2011;85:4122–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126222</ArticleId><ArticleId IdType="pubmed">21325420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine. 2021;71:3–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7657570</ArticleId><ArticleId IdType="pubmed">33179220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wambier CG, et al. Androgen sensitivity gateway to COVID -19 disease severity. Drug Dev Res. 2020;81:771–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273095</ArticleId><ArticleId IdType="pubmed">32412125</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard CE, et al. Sex versus gender-related characteristics: which predicts clinical outcomes of acute COVID-19? Intensive Care Med. 2022;48:1652–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361238</ArticleId><ArticleId IdType="pubmed">35943570</ArticleId></ArticleIdList></Reference><Reference><Citation>Okwan-Duodu D, Lim E-C, You S, Engman DM. TMPRSS2 activity may mediate sex differences in COVID-19 severity. Signal Transduct Target Ther. 2021;6:100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919249</ArticleId><ArticleId IdType="pubmed">33649313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker J, Baum MJ. Role for estradiol in female-typical brain and behavioral sexual differentiation. Front Neuroendocrinol. 2008;29:1–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373265</ArticleId><ArticleId IdType="pubmed">17720235</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocco C. Tissue physiology and pathology of aromatase. Steroids. 2012;77:27–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286233</ArticleId><ArticleId IdType="pubmed">22108547</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanelle-Bertram S, et al. CYP19A1 mediates severe SARS-CoV-2 disease outcome in males. Cell Rep Med. 2023;4:101152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10518605</ArticleId><ArticleId IdType="pubmed">37572667</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, et al. Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19. Sci Rep. 2022;12:9462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9175532</ArticleId><ArticleId IdType="pubmed">35676404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sund M, Fonseca-Rodríguez O, Josefsson A, Welen K. Fors Connolly, A.-M. Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study. BMJ Open. 2022;12:e053032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844968</ArticleId><ArticleId IdType="pubmed">35165090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott N, et al. Sex hormones in SARS-CoV-2 susceptibility: key players or confounders? Nat Rev Endocrinol. 2023;19:217–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9734735</ArticleId><ArticleId IdType="pubmed">36494595</ArticleId></ArticleIdList></Reference><Reference><Citation>Salciccia S, et al. Interplay between male testosterone levels and the risk for subsequent invasive respiratory assistance among COVID-19 patients at hospital admission. Endocrine. 2020;70:206–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543668</ArticleId><ArticleId IdType="pubmed">33030665</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastrelli G, et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV‐2 pneumonia patients. Andrology. 2021;9:88–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280645</ArticleId><ArticleId IdType="pubmed">32436355</ArticleId></ArticleIdList></Reference><Reference><Citation>Camici M, et al. Role of testosterone in SARS-CoV-2 infection: a key pathogenic factor and a biomarker for severe pneumonia. Int J Infect Dis. 2021;108:244–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135187</ArticleId><ArticleId IdType="pubmed">34023492</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin A, et al. Testosterone and Covid-19: an update. Rev Med Virol. 2023;33:e2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537909</ArticleId><ArticleId IdType="pubmed">36056748</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugh PJ, Channer KS, Parry H, Downes T. Hugh Jones, T. BIO-AVAILABLE TESTOSTERONE LEVELS FALL ACUTELY FOLLOWING MYOCARDIAL INFARCTION IN MEN: ASSOCIATION WITH FIBRINOLYTIC FACTORS. Endocr Res. 2002;28:161–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489566</ArticleId></ArticleIdList></Reference><Reference><Citation>Manwani B, et al. Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke. Biol Sex Differ. 2021;12:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792154</ArticleId><ArticleId IdType="pubmed">33413673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashar NAS, Gohar NMA-H, Tantawy AA, Kamel MH. M. evaluation of relationship between TMPRSS2 p.(Val197Met) variant and COVID-19 susceptibility and severity. BMC Infect Dis. 2024;24:112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10802041</ArticleId><ArticleId IdType="pubmed">38254046</ArticleId></ArticleIdList></Reference><Reference><Citation>Strope JD, PharmD CHC, Figg WD. TMPRSS2: potential biomarker for COVID-19 outcomes. J Clin Pharmacol. 2020;60:801–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280622</ArticleId><ArticleId IdType="pubmed">32437018</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzdorf K, et al. TMPRSS2 is essential for SARS-CoV-2 Beta and omicron infection. Viruses. 2023;15:271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9961888</ArticleId><ArticleId IdType="pubmed">36851486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>